275 related articles for article (PubMed ID: 33915503)
1. SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction.
Ahmed AS; Mona MM; Abdel-Kareem MA; Elsisy RA
Biomed Pharmacother; 2021 Jul; 139():111624. PubMed ID: 33915503
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats.
Kuno A; Kimura Y; Mizuno M; Oshima H; Sato T; Moniwa N; Tanaka M; Yano T; Tanno M; Miki T; Miura T
Sci Rep; 2020 Apr; 10(1):7238. PubMed ID: 32350374
[TBL] [Abstract][Full Text] [Related]
3. Diabetes increases the susceptibility to acute kidney injury after myocardial infarction through augmented activation of renal Toll-like receptors in rats.
Ohno K; Kuno A; Murase H; Muratsubaki S; Miki T; Tanno M; Yano T; Ishikawa S; Yamashita T; Miura T
Am J Physiol Heart Circ Physiol; 2017 Dec; 313(6):H1130-H1142. PubMed ID: 28822965
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Oshima H; Miki T; Kuno A; Mizuno M; Sato T; Tanno M; Yano T; Nakata K; Kimura Y; Abe K; Ohwada W; Miura T
J Pharmacol Exp Ther; 2019 Mar; 368(3):524-534. PubMed ID: 30552292
[TBL] [Abstract][Full Text] [Related]
5. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats.
Kimura Y; Kuno A; Tanno M; Sato T; Ohno K; Shibata S; Nakata K; Sugawara H; Abe K; Igaki Y; Yano T; Miki T; Miura T
J Diabetes Investig; 2019 Jul; 10(4):933-946. PubMed ID: 30663266
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
12. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Dekkers CCJ; Petrykiv S; Laverman GD; Cherney DZ; Gansevoort RT; Heerspink HJL
Diabetes Obes Metab; 2018 Aug; 20(8):1988-1993. PubMed ID: 29573529
[TBL] [Abstract][Full Text] [Related]
13. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
Baer PC; Koch B; Freitag J; Schubert R; Geiger H
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
[TBL] [Abstract][Full Text] [Related]
16. Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors.
Darawshi S; Yaseen H; Gorelik Y; Faor C; Szalat A; Abassi Z; Heyman SN; Khamaisi M
Ren Fail; 2020 Nov; 42(1):836-844. PubMed ID: 32787602
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY
Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268
[TBL] [Abstract][Full Text] [Related]
18. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
Elkazzaz SK; Khodeer DM; El Fayoumi HM; Moustafa YM
Life Sci; 2021 Sep; 280():119018. PubMed ID: 33549594
[TBL] [Abstract][Full Text] [Related]
19. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats.
Ala M; Khoshdel MRF; Dehpour AR
Oxid Med Cell Longev; 2022; 2022():1197061. PubMed ID: 35126806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
